regulatory
confidence high
sentiment negative
materiality 0.70
NEKTAR THERAPEUTICS (NKTR): Nasdaq/NYSE listing notice — Nektar gets Nasdaq bid-price extension to May 2024; stock moves to Capital Market
NEKTAR THERAPEUTICS
- Nasdaq granted additional 180-day period until May 20, 2024 to regain $1.00 minimum bid price.
- Common stock will transfer from Nasdaq Global Select to Nasdaq Capital Market on Nov 28, 2023.
- Company intends to cure deficiency via reverse stock split if needed before May 20, 2024.
- If compliance not regained, Nasdaq may delist NKTR; company can appeal to a Listing Qualifications panel.
- Stock continues to trade under symbol NKTR on the Nasdaq Capital Market.